Osteoarthritis and rheumatoid arthritis drive a large share of chronic-pain certifications, particularly among patients over 50 — one of the fastest-growing medical cannabis demographics. Patients report pain relief and better sleep; topicals are popular for localized joints.
Rheumatoid patients on immunosuppressants should coordinate with their rheumatologist. For most states, X-rays or a documented arthritis diagnosis makes certification straightforward under pain provisions.
The information on this site is for educational purposes only and is not medical or legal advice. Cannabis use carries risks; consult a licensed physician about whether medical cannabis is appropriate for you. Federal status (as of June 2026): marijuana dispensed under state medical licenses and FDA-approved cannabis products are Schedule III controlled substances; all other marijuana remains Schedule I under U.S. federal law.